Latest news
Heron Therapeutics Withdraws 2026 Guidance as CINVANTI Patent Risk and Strategic Review Cloud Outlook - Yahoo FinanceYahoo Finance · Mon, 10 Aug 2026 15:05:39 GMTHeron Therapeutics Q2 revenue rises on acute care growth, withdraws 2026 outlook - TradingViewTradingView · Mon, 10 Aug 2026 12:08:40 GMTHeron Therapeutics reports Q2 2026 revenue $37.7M, withdraws 2026 guidance after patent ruling - TradingViewTradingView · Mon, 10 Aug 2026 12:03:01 GMT